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ABSTRACT 
Background. Several studies demonstrated that cardiac resynchronization therapy (CRT) is 
effective in treating heart failure (HF) patients who are in sinus rhythm (SR) and that 
atrioventricular junction ablation (AVJA) improves prognosis in CRT patients with atrial 
fibrillation (AF).  We aimed to determine whether AVJA reduces incidence and burden of 
ventricular tachyarrhythmias (VT/VF) and of all-cause ICD therapies compared with treatment with 
rate-slowing drugs, in CRT patients with permanent AF. 
Methods. Pooled analysis of patient data from the  Advance CRT-D and Advance III randomized 
trials, and from the Italian ClinicalService® prospective observational project. Primary endpoint was 
the annual rate of all-cause ICD shocks.  
Results. A total of 3358 patients (2720 male, mean age 66.6 years) with CRT-ICD were included 
by 179 International centers;  2694 (80%) SR patients,  262  permanent AF patients treated with 
AVJA (AF+AVJA, 8%) and 402 AF patients treated with  rate-slowing drugs (AF+Drugs, 12%). 
Median follow-up was 18 months. The rate of all-cause shocks (95% confidence interval) per 100 
patient-years was 8.0 (5.3-11.9) in AF+AVJA, 43.6 (37.7-50.4) in AF+Drugs and 34.4 (32.5-36.5) 
in SR patients, with an incidence rate reduction (IRR) of 0.18 (0.10-0.32) comparing AF+AVJA 
with AF+Drugs (p<0.001) and IRR=0.48 (0.35-0.66) comparing AF+AVJA with SR (p<0.001). 
Also the rates of appropriate and inappropriate shocks, when considered separately, were reduced in 
patients with AF+AVJA compared with AF+Drugs and SR patients. 
Conclusions. CRT-D patients with permanent AF have lower incidence and burden of ICD shocks  
both appropriate and inappropriate, when treated with AVJA compared with rate control agents. 
Keywords: cardiac resynchronization therapy, atrio-ventricular junction ablation , heart failure, atrial fibrillation 
Introduction 
Cardiac resynchronization therapy (CRT) is an established treatment for patients with mild to 
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severe heart failure (HF), sinus rhythm (SR), a prolonged QRS duration, and impaired left 
ventricular (LV) systolic function. (1-4) In the CARE-HF (Cardiac Resynchronization in Heart 
Failure) study (4), CRT was associated with 40% relative reduction in all-cause mortality. This and 
other studies have shown that CRT also improves symptoms, exercise capacity, and quality of life, 
and induces LV reverse remodeling. (5-6) 
It is well recognized that the development of atrial fibrillation (AF) in HF heralds a poor prognosis. 
(7-9) There is also evidence to suggest that CRT may not be as effective for patients with AF. (10-
15). That may be due to several factors. Firstly, AF precludes atrioventricular optimization of CRT. 
Secondly, a high intrinsic ventricular response leads to electrical fusion and pseudo-fusion beats 
reducing biventricular pacing capture and, consequently, CRT benefits. Most randomized controlled 
CRT trials have excluded patients with AF. Yet, among the general HF population, AF is common, 
occurring in 10% to 25% of patients in New York Heart Association (NYHA) class II to III and in 
as many as 50% of patients in NYHA class IV. (16) 
Rate-slowing drugs have been the mainstay of treatment for the control of the ventricular response 
in patients with AF. Atrioventricular junction ablation (AVJA) has also been used as an alternative 
to drug therapy for controlling the ventricular response in patients with permanent AF. (17) 
Observational studies have suggested that, in patients with HF and permanent AF undergoing CRT, 
AVJA is associated with a longer survival compared to treatment with rate-slowing drugs. (10-11, 
18). In this large international, multicenter research we pooled data from studies on CRT ICD 
(CRT-D) to evaluate VT/VF incidence and ICD therapies in patients with permanent AF, treated by 
AVJA or rate-slowing drugs, and in patients in SR. 
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Methods 
Design 
We performed a pooled analysis of individual patient data from two prospective, international 
randomized studies, Advance CRT-D (19) and Advance III (20), and from the Italian 
ClinicalService® prospective observational project. Only patients treated with a CRT-D device have 
been included in this analysis. 
Advance CRT-D (ClinicalTrials.gov identifier: NCT00147290) was a prospective, randomized 
study designed to assess the efficacy of biventricular versus right ventricular antitachycardia pacing 
(ATP) in terminating all kinds of ventricular arrhythmias (VT/VF) with 526 patients enrolled from 
60 European sites. Study methods and results have been already described. (19) 
Advance III (ClinicalTrials.gov identifier: NCT00617175) was a prospective, randomized study 
designed to assess whether using long detection intervals to detect VT/VF reduces ATP and shock 
delivery with 1902 patients enrolled from 94 sites in Europe and Asia. Study methods and results 
have been already described. (20)   
The Italian ClinicalService® Project (ClinicalTrials.gov.identifier: NCT01007474) is a national 
cardiovascular data repository and a prospective medical care project aimed at describing and 
improving the use of implantable cardiac devices in about 150 Italian cardiology centers.  
The analysis set includes patients enrolled in 14 countries, in particular Belgium, Denmark, France, 
Germany, Hungary, Israel, Italy, Portugal, Russia, Saudi Arabia, South Africa, Spain, The 
Netherland, and UK.  
Data collection and analysis was approved by the individual sites’ institutional review board or 
clinical ethics committee and conformed to the Declaration of Helsinki. All patients gave written, 
informed consent for data collection and analysis.  
Patient population 
Patients were eligible for the pooled database if they were implanted with a CRT-D according to 
international guidelines (systolic HF in NYHA class III or ambulatory IV, or II in the case of a 
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recent HF hospitalization); LVEF≤35% and QRS≥120 ms, despite maximum tolerated 
pharmacologic therapy and had at least 3 months of follow-up and device diagnostic data available.  
Our analysis involved 3358 patients who underwent CRT-D implantation in the period from 
February 2004 to December 2014 in 179 cardiological centers in Europe and Asia (see Appendix).  
Clinical assessment and follow-up 
Baseline clinical assessments were undertaken before CRT-D implantation and included evaluation 
of NYHA class, an electrocardiogram, and a transthoracic echocardiogram. The following 
parameters were assessed according to the Simpson’s biplane method: LV end-diastolic volume, 
LV end-systolic volume (LVESV), and LVEF. (21)  
Advance CRT-D and Advance III studies had specified follow-up visits, while in the Italian 
ClinicalService® clinical follow-ups and device interrogations were performed according to the 
routine practice of the participating centers.  
Rate control strategies 
Rate-slowing drugs were given to all AF patients before device implantation and were up-titrated 
after implantation to reach adequate rate control (22), and to maximize the biventricular pacing 
capture. The AVJA was performed within 3 months if adequate biventricular pacing percentage did 
not occur with rate-slowing drugs. (12)  
Patient groups 
Patients with permanent AF and AVJA performed within 3 months from implant were considered 
in the AF+AVJA group. Patients with permanent AF and rate control drugs, who were not treated 
by AVJA, were considered in the AF+Drugs group. Patients without permanent AF were 
considered in the SR group. In case AVJA was performed during follow-up in SR and AF+Drugs 
patients’, the observation period was censored at the time of the ablation.  In all patients, the follow-
up exposure was trunked at 18 months.  
Objectives and endpoints 
Aim of this analysis was to compare the 3 groups in term of incidence and burden of ICD detections 
and ICD therapies (ATP and shocks), overall as well as appropriate and inappropriate. The primary 
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endpoint was the annual rate of any cause ICD shocks. Secondary endpoints were 1) annual rate of 
appropriate shocks, 2) annual rate of inappropriate shocks, 3) incidence of all-cause, appropriate, 
and inappropriate shocks. We also evaluated all-cause and heart failure  hospitalizations.  
Appropriateness of all sustained ventricular tachycardias, ventricular fibrillations, and monitored 
ventricular tachycardias detected by implanted devices was analyzed by 2 members of a blind 
episode review committee (ERC) who reviewed episodes plots and electrograms. In the case of 
disagreement between the 2 reviewers, the episode was submitted to a third independent reviewer.  
Device therapy 
Transvenous CRT-D implantation was undertaken using standard transvenous techniques under 
local anesthesia. A lateral or posterolateral LV site was considered optimal for LV lead by most 
implanters. In patients with SR, the CRT device was programmed in atrial-synchronous sequential 
pacing. Atrioventricular optimization was undertaken within 24 hours of device implantation and at 
6 months, using Doppler echocardiography and the iterative method (20). For patients with AF, the 
minimum heart rate was set at ≥70 beats/min and the maximum rate was set at 70% of the 
theoretical maximum heart rate.  
Statistical analysis  
Continuous variables were expressed as means and standard deviations or median and interquartile 
range (IQR), as appropriate. Categorical variables were expressed as counts and percentages.  
Baseline characteristics were compared between groups by means of the chi-square test or the 
Kruskal-Wallis test as appropriate. Analysis of primary endpoints (all-cause ICD shocks) as well as 
analysis of appropriate detections and therapies, followed the same approach and the same blind 
review that was used in the Advance III trial. (20)  Rates were computed for 100 person years and 
were compared by means of the Poisson model using the scale deviation parameter to adjust for 
over-dispersion. Incidence rate ratios (IRRs) with their 95% confidence intervals (95%CI) were 
computed to measure episodes and hospitalizations reduction in the AF+AVJA group.  IRRs were 
also adjusted to account for the effect of potential confounders in the comparison between 
AF+AVJA and AF+Drugs. Freedom from ICD detection or therapy, and from hospitalization were 
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studied by means of a Cox model and Kaplan–Meier curves were reported. Univariate hazard ratios 
(HRs) with their 95%CI were reported. An alpha-level of 0.05 was considered for each test. All 
statistical analyses were performed by using SAS 9.4 version software (SAS Institute Inc., Cary, 
NC, USA). 
Results 
A total of 3358 patients with CRT ICD were included in the analysis; patients were classified into 3 
groups, 2694 (80%) SR patients, 402 AF+drugs patients (12%) and 262 AF+AVJA patients 
(8%).Patient characteristics are shown in Table I; patients with AF were older, less likely to have an 
ischemic cardiomyopathy or previous acute myocardial infarction (AMI) or a large QRS and had 
smaller LV dimensions. Comparing patients with AF+AVJA and patients with AF+drugs, the 
former had slightly higher LVEF and were less  likely to have left bundle branch block. 
In a median (IQR) follow up of 18 (12-18) months, ICD episodes and therapies were collected, 
reviewed by the blind ERC and defined as appropriate or inappropriate as described in figure 1. 
Primary endpoint – all-cause ICD shocks 
Annual rate of all-cause ICD shocks was 8.0 per 100 patient years in the AF+AVJA, 43.6 per 100 
patient years in the AF+Drugs group and 34.4 (32.5 - 36.5) in SR group leading to a significant 
82% reduction (IRR (95%CI)=0.18 (010-0.32), p<0.001) comparing AF+AVJA vs. AF+Drugs as 
shown in figure 2 section A and a significant 52% reduction (IRR (95%CI)=0.48 (0.35 - 0.66), p<0-
001) comparing AF+AVJA vs. SR as shown in figure 2 section B.  
A significant IRR reduction (IRR (95%CI)=0.31 (0.17-0.56), p<0.001) comparing AF+AVJA vs. 
AF+Drugs was confirmed after correction for LVEF and LBBB which were patients’ baseline 
characteristics which resulted as different between AF+AVJA an AF+Drugs groups. 
Together with all-cause shocks, also all-cause ICD detections and ATP showed a significantly 
(p<0.001) lower annual rate in AF+AVJA group compared with both AF+Drugs group and SR 
group (tables 0:1-0:3 in appendix supplementary data). 
AF+Drugs patients showed a trend toward higher annual rate of all-cause ICD shocks vs. SR 
patients, as shown in figure 2 section C.   
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Secondary endpoints 
AF+AVJA patients showed significantly higher freedom from all-cause ICD shocks compared with  
AF+Drugs patients or SR patients, as shown in figure 3A. 
Appropriate detections and therapies 
The annual rate of appropriate ICD shocks was 6.6  per 100 patient years in the AF+AVJA, 28.7 per 
100 patient years in the AF+Drugs group and 19.5 (18.0 - 21.0) in the SR group, leading to a 
significant 77% reduction (IRR (95%CI)=0.23 (0.13-0.40), p<0.001) comparing AF+AVJA and 
AF+Drugs as shown in figure 2 section A, and a significant 42% reduction (IRR (95%CI)=0.58 
(0.44 - 0.77), p<0.001) comparing AF+AVJA and SR as shown in figure 2 section B.  
A significant IRR reduction comparing AF+AVJA vs. AF+Drugs was confirmed after correction 
for LVEF and LBBB (IRR (95%CI)=0.50 (0.29-0.87), p=0.015).   
AF+Drugs patients showed significantly higher annual rate of appropriate ICD shocks vs. SR 
patients, as shown in figure 2 section C.   
Patients with AF+AVJA showed lower incidence (figure 3B) of appropriate shocks both compared 
with AF+Drugs and SR patients.  
Together with appropriate shocks, also appropriate ICD detections and ATP showed a significantly 
(p≤0.003) lower annual rate in AF+AVJA group compared with both AF+Drugs group and SR 
group (tables 0:4-0:6 in appendix supplementary data). 
Inappropriate detections and therapies 
The annual rate of inappropriate ICD shocks was 1.3  per 100 patient years in the AF+AVJA, 14.9 
per 100 patient years in the AF+Drugs group and 15.0 (13.7-16.4) in the SR group leading to a 
significant 91% reduction (IRR (95%CI)=0.09 (0.04-0.21), p<0.001) between AF+AVJA and 
AF+Drugs as shown in figure 2 section A and a significant 70% reduction (IRR (95%CI)=0.30 
(0.17 - 0.52), p<0.001) between AF+AVJA and SR as shown in figure 2 section B.  
A significant IRR reduction was confirmed when comparing AF+AVJA vs. AF+Drugs after 
correction for LVEF and LBBB (IRR (95%CI)=0.09 (0.03-0.26), p<0.001). 
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Together with inappropriate shocks, also inappropriate ICD detections and ATP showed a 
significantly lower (p<0.001) annual rate in AF+AVJA group compared with both AF+Drugs group 
and SR group (tables 0:7:0.9 in appendix supplementary data). 
Annual rate of inappropriate ICD shocks was not different between AF+Drugs patients and SR 
patients, as shown in figure 2 section C.   
Patients with AF+AVJA showed lower incidence (figure 3C) of inappropriate shocks both 
compared with AF+Drugs (p=0.003) and SR (p=0.019) patients.  
Most inappropriate detections and therapies were due to AF, in particular AF was the cause for 
inappropriate detections in 1104/1405 (78.6%) episodes and in 270/334 (80.8%) of patients with 
inappropriate detections; moreover 300/359 (83.6%) episodes with inappropriate ICD shocks were 
due to AF. However patients in the AF+ AVJA group were almost free from inappropriate VT/VF 
detections induced by AF; only 6/262 (2.3%) patients had one AF-related inappropriate detection 
and only 2 (0.8%) patients suffered 1 single shock each in 1 episode. Annual rate of AF-related ICD 
shocks was 0.7 per 100 patient years in the AF+AVJA, 11.6 per 100 patient years in the AF+Drugs 
group and 12.6 per 100 patient years in the SR group leading to a significant 94% reduction (IRR 
(95%CI)=0.06 (0.02-0.166), p<0.001) comparing AF+AVJA vs. AF+Drugs and a significant 77% 
reduction (IRR (95%CI)=0.23 (0.11-0.48), p<0.001) comparing AF+AVJA vs. SR. Together with 
AF-related inappropriate shocks, also AF-related inappropriate ICD detections and ATP showed a 
significantly (p<0.001) lower annual rate in AF+AVJA group compared with both AF+Drugs group 
and SR group (tables 0:10-0:12 in appendix supplementary data). 
Overall and heart failure hospitalizations  
During follow-up 684 patients were hospitalized for any reason, in particular 557 (20.7%) in the SR 
group, 88 (33.1%) in the AF+Drugs group and 39 (18.1%) in the AF+AVJA group. Annual rate of 
all-cause hospitalizations for the AF+AVJA patients were significantly lower than in AF+Drugs or 
SR groups, as shown in table II. 
During follow-up 234 patients were hospitalized for heart failure, in particular 191 (7.1%) in the SR 
group, 30 (7.5%) in the AF+Drugs group and 13 (5.0%) in the AF+AVJA group.  
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Annual rate of heart failure hospitalization for 100 patient years were 8.0 (7.9-8.1) in SR patients, 
9.5 (9.2-9.7) in the AF+Drugs group and 5.0 (4.8-5.1) in the AF+AVJA group leading to a 
significant 48% reduction (IRR (95%CI)=0.52 (0.35-0.78) p=0.002) comparing AF+AVJA and 
AF+Drugs patients and a 21% significant reduction (IRR (95%CI)=0.79 (0.65-0.95) p=0.016) 
comparing AF+AVJA and SR patients, as shown in table III.  
Discussion 
Main results 
By comparing CRT-D patients with permanent AF we found that the strategy of AVJA was 
associated with lower burden and incidence of all-cause ICD shocks, and that this result was driven 
by reductions of both appropriate and inappropriate shocks. Importantly these reductions were 
confirmed also comparing CRT-D patients with permanent AF treated by AVJA vs. CRT-D 
patients in sinus rhythm. Moreover also the annual rates of appropriate or inappropriate detections 
and ATP resulted significantly reduced by AVJA compared with AF patients treated with rate 
control agents and with SR patients.  
These findings are of particular relevance, given that no randomized controlled trial have compared 
AVJA and rate control drugs strategies in CRT-D recipients, although the prevalence of permanent 
AF in such CRT population  approaches 25% (24-25). So far only some observational studies (11-
12, 18) and two meta-analyses (26-27) have evaluated these two rate control strategies and have 
suggested that for CRT patients with AF, AVJA is associated with better clinical outcome and a 
>50% reduction in all-cause mortality, compared with rate-slowing drugs. It is on this basis that 
both the European Society of Cardiology (ESC) and the American Heart Association guidelines 
(28-29) now consider patients with HF and permanent AF as candidates for CRT (Class IIa, level of 
evidence B), provided 100% of biventricular pacing is obtained, and, if not, AVJA should be 
considered. Our data on the incidence and burden of arrhythmic events adds new insight and 
provide further evidence of the benefit associated with AVJA in AF patients treated with CRT. 
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In this analysis patients with permanent AF and treated by AVJA were almost free from 
inappropriate VT/VF detections induced by AF; the few cases observed were probably associated to 
patients in which AV Junction ablation or modulation was not complete. 
The fact that AVJA may reduce AF-related inappropriate ICD detections and therapies may be 
expected but at the best of our knowledge it has not been described so far.  
 The observation that AVJA may reduce also appropriate ICD detections and therapies is an 
important and intriguing finding that we associate with the known fact that patients with low 
ejection fraction during rapid AF may suffer VT/VF episodes and with the fact that rapid AF often 
negatively impact on CRT, by reducing biventricular pacing, and therefore worsen patient status; 
indeed Hayes et al. (30) in a large cohort of 36,935 CRT patients followed up in a remote-
monitoring network showed that AF significantly limits the capability to perform cardiac 
resynchronization and that a biventricular pacing higher than 98% of all ventricular beats is 
associated with mortality reduction.  
The observation that also patients classified in the SR group had higher incidence of both AF-
related inappropriate ICD detection and therapies and appropriate ICD detection and therapies may 
be explained by the fact that paroxysmal AF is a frequent comorbidity of CRT patients and that 
new-onset AF is also a frequent finding in the follow-up of this patient population.  
Clinical outcomes 
Our data confirm that AVJA significantly reduces all-cause and HF hospitalizations. This finding 
favorably compares with the results of previous studies and meta-analyses (11-12, 18, 26-27) which 
showed reduced mortality in patients treated by AVJA compared with patients treated by rate 
control agents. 
It is important to outline that the reduction of ICD therapies, particularly of ICD shocks, has usually 
a positive impact on patient’s quality of life and therapy acceptance and may improve patient 
health; indeed several authors have hypothesized that ICD shocks are causally associated with poor 
prognosis. (31-32) 
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Clinical implications 
Despite AVJA is indicated in AF CRT patients by both European Society of Cardiology and the 
American Heart Association guidelines (28-29) to provide 100% biventricular pacing, AVJA is still 
underused, likely because this practice makes patients pacemaker dependent. Several observational 
studies (11-12, 18) and two meta-analyses (26-27) have shown that, in CRT patients with AF, 
AVJA is associated with better clinical outcomes in terms of improved reverse remodeling, work 
capacity and survival, compared with rate-slowing drugs. Our data now show that AVJA in AF 
CRT patients is associated with a clinically significant reduction of ICD therapies. Importantly the 
observation of a lower incidence of appropriate episodes, associated with a lower incidence of ICD 
shocks and reduced occurrence of all-cause and HF hospitalizations, suggests that AVJA may 
determine an improved prognosis in these patients.  
In our opinion compelling evidence has therefore been accumulated to reinforce the use of AVJA in 
patients with permanent AF indicated to CRT therapy. 
Study limitations 
We recognize that our analysis has some limitations. Assigning AVJA or rate control drugs was not 
randomized, rather left to the practice of cardiologists involved in the three clinical projects from 
which we gathered data. Therefore there may be confounding factors associated, for example, with 
possible differences in the patients’ populations or in the follow-up timing between the three 
projects from which we gathered data. We tried to optimize scientific methodology by pre-
specifying analyses objectives before dataset opening and by correcting arrhythmic events risk for 
most important patients’ characteristics, in particular for those which differed among analyzed 
groups. Moreover a homogeneous review of ICD detections and therapies was performed in all 
patients groups by a blind ERC. (20)  
Conclusions 
CRT-D patients with permanent AF have lower rate and incidence of ICD shocks, ATP and 
detections, both appropriate and inappropriate, when treated with AVJA compared with rate control 
agents. Moreover AVJA is associated to a lower incidence of all-cause and HF hospitalizations. 
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Further randomized studies on the role of AVJA in patients with AF undergoing CRT are 
warranted. 
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Figure legends 
Figure 1. Number of patients in each research group and number of patients with ICD detection, 
ATP and shocks, overall and for appropriate and inappropriate episodes respectively 
Figure 2. Incidence rate ratio and annual rate of all-cause ICD shocks, appropriate ICD shocks and 
inappropriate ICD shocks comparing AF+AVJA patients vs. AF+Drugs patients (section 
A), comparing AF+AVJA patients vs. SR patients (section B), and comparing AF+Drugs 
patients vs. SR patients (section C) 
Figure 3. Time to first all-cause ICD shock (section A), first appropriate ICD shock (section B) and 
first inappropriate ICD shock (section C) 
 
 
 
20 
 
20 
Table I : Baseline characteristics according to patient group  
 
 
Patient 
Characteristics 
SR                        
(N = 2694) 
AF+Drugs  
(N = 402) 
AF+AVJA  
(N = 262) 
p 
value 
Post-hoc 
comparisons * 
Demographics 
Age at first implant 
(years) 
66 ± 10 69 ± 9 69 ± 10 <0.001 1,3 
Male 79.8% 87.3% 83.8% 0.001 1 
Medical history 
Ischemic 
Cardiomyopathy 
53.3% 44.1% 43.0% <0.001 1, 3 
AMI 49.1% 40.9% 33.2% <0.001 1, 3 
NYHA III-IV 67.9% 68.4% 76.8% 0.015  
Ventricular  
arrhythmias 
36.5% 32.7% 31.7% 0.15  
VF/Flutter 5.0% 6.3% 5.3% 0.56  
LBBB 58.1% 53.0% 40.4% <0.001 2, 3 
QRS ≥ 120 ms 92.8% 85.8% 78.7% <0.001 1, 3 
Echo parameters 
LVEF (%) 26 ± 6 27 ± 6 28 ± 5 <0.001 2,3 
LVESD (mm) 58 ± 12 55 ± 11 53 ± 8 <0.001 1, 3 
LVEDD (mm) 68 ± 10 66 ± 9 63 ± 8 <0.001 2,3 
LVESV (dl) 154 ± 60 141 ± 60 132 ± 61 <0.001 1, 3 
LVEDV (dl) 206 ± 72 200 ± 75 181 ± 60 <0.001 3 
 
AVJA=atrioventricular junction ablation, SR=sinus rhythm, AF=atrial fibrillation, AMI=acute 
myocardium infarction, NYHA=New York Heart Association, VF= ventricular fibrillation, 
LBBB=left bundle branch block, LVEF=left ventricle ejection fraction, LVESD=left ventricle end 
systolic diameter, LVEDD=left ventricle end diastolic diameter, LVESV=left ventricle end systolic 
volume, LVEDV=left ventricle end diastolic volume, 
* Post-hoc comparisons are as follows: 1) SR vs. AF+Drugs; 2) AF+AVJA vs. AF+Drugs; 3) SR 
vs. AF+AVJA. 
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Table II : All-cause hospitalizations 
Rhythm 
group 
 
Patients with 
all-cause 
hospitalization 
All-cause 
hospitalizations 
(n) 
 
All-cause 
hospitalization annual 
rate * 100  
patient/years (95%CI) 
 
Incidence rate ratio  
(95%CI) 
 
p-value 
SR 557 (20.7%) 808 24.4 (24.1 - 24.6)   
AF+DRUG 88 (33.1%) 130 30.8 (29.9 - 31.6) 1.26 (1.04-1.54) vs. SR 0.020 
AF+AVJA 39 (18.1%) 53 17.6 (17.0 - 18.1) 
0.85 (073-0.98) vs. SR 
0.57 (0.41-0.79) vs. AF+Drugs 
0.027 
<0.001 
 
Table III : HF hospitalizations 
Rhythm 
group 
 
Patients with 
HF  
hospitalization 
HF  
hospitalizations 
(n) 
 
HF  hospitalizations 
annual rate * 100  
patient/years (95%CI) 
Incidence rate ratio (95%CI) p-value 
SR 191 (7.1%)  265 8.0 (7.9-8.1)   
AF+DRUG 30 (7.5%)  40 9.5 (9.2-9.7) 1.18 (0.92-1.52) vs. SR 0.183 
AF+AVJA 13 (5.0%)  15 5.0 (4.8-5.1) 
0.79 (0.65-0.95) vs. SR 
0.52 (0.35-0.78) vs. AF+Drugs 
0.016 
0.002 
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Figure 1 
 
AF = atrial fibrillation; AVJA = atrioventricular junction ablation; SR = sinus rhythm 
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Figure 2 
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Figure 3 
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Appendix – Research Committees 
Advance CRT-D Steering Committee  
Frederic Anselme, Jacques Clementy, Maurizio Gasparini, Jose Bautista Martinez Ferrer, Massimo 
Santini, Jeorg O. Schwab 
Advance III Steering Committee  
ÁngelArenal, Maurizio Gasparini, A Hersi, Kloppe, Maurizio Lunati, Alessandro Proclemer, Jose 
Bautista Martinez Ferrer, M Wijffels 
ClinicalService Scientific Committee  
Mauro Biffi, Giuseppe Boriani, Maurizio Gasparini, Maurizizo Landolina, Maurizio Lunati, 
Alessandro Proclemer, Renato Ricci, Roberto Rordorf 
 
Appendix – Research Participating Centres 
IRCCS Humanitas Research Hospital – Rozzano (Milano); Ospedale Niguarda Ca Granda – 
Milano; Policlinico San Matteo – Pavia; Ospedale Civile Maggiore di Borgo Trento –Verona; Az. 
Ospedaliera S.Maria della Misericordia – Udine; Ospedale Mater Salutis di Legnago – Legnago; 
Ospedale San Filippo Neri (Roma); Ospedale Santa Maria Del Carmine - Rovereto (TM); A.S. 
Ospedaliera S. Croce e Carle – Cuneo; Ospedale San Raffaele – Milano; Villa S. Anna S.p.A. – 
Catanzaro; Klinikum Lüdenscheid (Lüdenscheid); Azienda Ospedaliera Sacro Cuore Don Calabria 
– Negrar; H. Txagorritxu (Vitoria); Hôpital Cardiologique (Bordeaux); Ist. Auxologico Italiano-
Ospedale S.Luca – Milano; Ospedale Civile G. Mazzini – Teramo; Osp. S. Maria degli Angeli – 
Pordenone; Policlinico Sant Orsola-Malpighi – Bologna; Ente Ospedaliero Ospedali Galliera – 
Genova; Rheinische Friedrich-Wilhelm-Universität Bonn; Centre Hospitalier de Pau; Ospedale 
Santa Maria della Misericordia – Rovigo; Azienda Ospedaliera Careggi – Firenze; Ospedale SS. 
Antonio e Biagio – Alessandria; ULSS N.6 S. Bortolo – Vicenza; Ospedale San Carlo Borromeo – 
Milano;  
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Ospedale Humanitas Gavazzeni – Bergamo; Ospedale Luigi Sacco – Milano; Hôpital Michalon- 
CHU Grenoble; Ospedale San Gerardo – Monza; Ospedale S.Anna – Como; Ospedale Belcolle – 
Viterbo; H. Ramón y Cajal; Ospedale Loreto Mare – Napoli; AZ. Osp. Ordine Mauriziano Torino; 
Hospital de Santa Maria; UNITAS Hospital; Osp. S. Giovanni di Dio e Ruggi d’Aragona – Salerno; 
Hospital Universitario de Canarias; Azienda Ospedaliera Pugliese e Ciaccio – Catanzaro; Ospedale 
Civile dello Spirito Santo – Pescara; Hospital Clinico de Malaga - Virgen de la Victoria; Hôpital 
Charles Nicolle (Rouen); Azienza Ospedaliera Spedali Civili – Brescia; Az. Osp. Molinette 
S.Giovanni Battista – Torino; Ospedale Vito Fazzi – Lecce; Ospedale Sandro Pertini – Roma; 
Hospital General Universitario Gregorio Marañón (Madrid); Presidio ospedaliero C.e G. Mazzoni -
Ascoli Piceno; Ospedale Misericordia e Dolce – Prato; King Khalid Univ. Hospital - King Saud 
University; Zentralklinik Bad Berka Kardiologie (Bad Berka); Hospital Ntra. Sra. de la Candelaria; 
Ospedale Civile di Conegliano - Conegliano Veneto; Diakoniekrankenhaus Rotenburg; Ospedale 
Civile – Asti; Ospedali Riuniti – Bergamo; Ospedale Sant Eugenio – Roma; St. Antonius 
Ziekenhuis Nieuwegein; CHU Hôpital Pasteur (Nice); Clinique Pasteur; Ospedale Civile G. 
Fornaroli – Magenta; Osp. San Giovanni Calibita Fatebenefratelli – Roma; A.O. Carlo Poma - 
Pieve di Coriano (MN); Ospedale Regionale San Maurizio – Bolzano; Azienda Ospedaliera San 
Salvatore – Pesaro; Az. Osp. Ca Foncello – Treviso; Medisch Spectrum Twente; Hôpital Trousseau 
(Tours); Ospedale S. Paolo P.M. – Milano; Azienda Ospedaliera Vittorio Emanuele Ferrarotto - S. 
Bambino (Catania); Ospedale Ferrarotto – Catania; NCN Nantes; Ospedale di Circolo - Desio (MI); 
Ospedale Fatebenefratelli e Oftalmico – Milano; Presidio Ospedaliero Riunito – Ciriè; P.O. di 
Montebelluna – Montebelluna; Nuovo Osp. Civile S. Agostino - Estense di Modena; Tyumen 
Cardiology Center; Hospital Universitario Virgen de las Nieves; CHU Nantes - Hôpital Guillaume 
et René Laënnec; Osp. S. Orsola-Fatebenefratelli – Brescia; Ospedale P. Cosma – Camposampiero; 
Casa di Cura Mater Domini – Castellanza; Hospital Virgen de La Salud; Hospital Clinico 
Universitario de Valencia; Ospedale di Circolo - Busto Arsizio (VA); Ospedale Civile di Mirano – 
Mirano; Ospedale Maggiore (Lodi); King Fahd Armed Forces Hospital; Hospital La Paz (Madrid); 
Hospital Virgen de las Nieves (Granada); CHU Hôpital de Pontchaillou Rennes; Sheba Medical 
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Center; Ospedale SS. Annunziata – Chieti; Ospedale Giovan Battista Grassi – Ostia; Hospital Geral 
de Santo António; Hopital St-Joseph; Chuvi-Xeral-Cíes; Hospital Universitario de San Juan; Centre 
Hospitalier Universitaire de Rennes; Hôpital Arnaud de Villeneuve (Cardiologie B) (Montpellier); 
Stab. Ospedaliero Di Summa-Perrino – Brindisi; Ospedale Civile - Legnano (MI); Centro Cuore 
Morgagni - Pedara (CT); Facoltà di Medicina e Chirurgia – Bari; Ospedale Bianchi-Melacrino-
Morelli (Reggio Calabria); Hospital de Santa Marta; H. Germans Trias i Pujol (Badalona); Hôpital 
Arnaud de Villeneuve (Cardiologie A) (Montpellier); Hôpital Européen George Pompidou (Paris); 
Hôpital Henri Mondor (Créteil); Ospedale Civile - Arzignano (VI); Casa di Salute Montevergine - 
Mercogliano (AV); Ospedale L. P. Delfino ASL Roma G – Colleferro; Fond. Ist. S.Raffaele-G. 
Giglio – Cefalù; Policlinico Casilino – Roma; Azienda Ospedaliera di Padova – Padova; Ospedale 
S. Giacomo - Novi Ligure; Azienda Ospedaliera Maggiore della Carita (Novara); University of 
Cape Town - Groote Schuur Hospital; Universität Rostock– Medizinische Fakultät; Kliniken Essen 
Nordwest Philippusstift Krankenhaus (Essen); Hospital General Universitario de Alicante; 
Ospedale di Manerbio-Leno - Manerbio (BS); Ospedale S.Pietro Igneo - Fucecchio (FI); S. Maria 
Nuova Hospital - Reggio Emilia; Ospedale S. Donato (San Donato Milanese MI); Hospital Garcia 
Orta; SA; CHR La Citadelle Liege; CHU Brugmann; Klinikum Dortmund; Hospital General San 
Pedro de Alcantara; Hospital de Donostia; CH Rangueil Toulouse; Centre Hospitalier - Aix en 
Provence; Centre Hospitalier (La Rochelle); Semmelweis University AOK; Tel-Aviv Sourasky 
Medical Center (Tel-Aviv); Azienda Ospedaliera Carlo Poma – Mantova; Ospedale di Desenzano - 
Desenzano del Garda; Ospedale Maggiore - Policlinico – Milano; Ospedale Civile di Vimercate – 
Vimercate; Presidio Ospedaliero di Milazzo (AUSL 5) – Milazzo; Ospedale S. Maria delle Croci – 
Ravenna; Ospedale G. Moscati – Avellino; Azienda Ospedaliera Bolognini – Seriate; Fondazione 
Poliambulanza – Brescia; Azienda Ospedaliera G. Rummo; Osp. Villa San Pietro Fatebenefratelli – 
Roma; Ospedale S. Spirito - Casale Monferrato (Alessandria); Ospedale Policlinico A. Gemelli 
(Roma); Hospital Santa Maria (Lisbon); John Radcliffe (Oxford); AZ Nikolaas; CHR Namur; 
Universitätskliniken des Saarlandes; Kardiologisches Zentrum an der Klinik Rotes Kreuz; RWTH 
Aachen; Odense Universitets Hospital; Hospital General Yagüe; Hospital General de Ciudad Real; 
 
 
28 
 
28 
Institut Arnaud Tzanck (St Laurent du Var); Hôpital de la Timone (Marseille); Hôpital Nord (St 
Etienne); Hôpital Lariboisière (Paris); Hôpital Béclère (Clamart); Sheba Medical Center; Ospedale 
di Circolo Galmarini - Tradate (VA); Ospedale Treviglio-Caravaggio - Treviglio (BG); Ospedale 
SS. Giacomo e Cristoforo – Massa; Osp. Santa Maria delle Grazie - Pozzuoli (NA); Ospedale San 
Vincenzo – Taormina; Casa di Cura Villa Verde – Taranto; A.U.S.L. - Osp. Guglielmo da Saliceto 
di Piacenza; Ospedale Oglio Po - Vicomoscano di Casalmaggiore; Presidio Ospedaliero di Venere - 
Bari Carbonara; Az. ULSS 12 Veneziana - Osp. Dell Angelo – Mestre.  
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Appendix – supplementary data  
All-cause detections, ATP and shocks 
TABLE 0:1 – ALL-CAUSE DETECTIONS 
Rhythm group Number of   detection 
Rate of detections * 100 
patient/years 
(95%CI) 
Incidence rate ratio  
(95%CI) 
p-value 
SR 4205 127 (123 -  131)   
AF+DRUG 598 142 (131 -  153) 1.12 (0.90 - 1.39) vs. SR 0.32 
AF+AVJA 154 51.1 (43.6 - 59.8) 
0.63 (0.52 - 0.78) vs. SR  
0.36 (0.24 - 0.53) vs. AF+DRUG 
<0.001 
<0.001 
TABLE 0:2 – ALL-CAUSE ATP 
Rhythm 
group 
Episodes 
with ATP   
ATP Rate of  ATP *100 
patient/years 
(95%CI) 
Incidence rate ratio  
(95%CI) 
p-value 
SR 2865 3694 111 (108 -  115)   
AF+DRUG 421 521 123 (113 -  134) 1.11 (0.87 - 1.41) vs. SR 0.41 
AF+AVJA 137 141 46.7 (39.6 - 55.1) 
0.65 (0.52 - 0.81) vs. SR 
0.38 (0.25 - 0.57) vs. AF+AVJA 
<0.001 
<0.001 
TABLE 0:3 – ALL-CAUSE SHOCKS 
Group 
Number of episodes with all 
cause shocks 
Rate of  episodes with all cause 
shocks *100 patient years 
(95%CI) 
Incidence rate ratio  
(95%CI) 
p-value 
SR 803 24.2 (22.6 - 25.9)   
AF+DRUG 147 34.8 (29.6 - 40.9) 1.44 (1.14 - 1.81) vs. SR 0.002 
AF+AVJA 20 6.6 ( 4.3 - 10.3) 
0.52 (0.39 - 0.69) vs. SR  
0.19 (0.11 - 0.33) vs. AF+DRUG 
<0.001 
<0.001 
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Appropriate detections, ATP and shocks 
TABLE 0:4 – APPROPRIATE DETECTIONS 
Rhythm  
group 
Number of  
appropriate 
detections 
Rate of  appropriate  
detections*100 
patient/years 
(95%CI) 
Incidence rate ratio  
(95%CI) 
p-value 
SR 2993 (536) 90.3 (87.1 - 93.5)   
AF+DRUG 419 (69) 99.3 (90.2 -  109) 1.10 (0.87 - 1.40) vs. SR 0.44 
AF+AVJA 140 (24) 46.4 (39.3 - 54.8) 
0.70 (0.60 - 0.82) vs. SR 
0.47 (0.32 - 0.69) vs. AF+DRUG 
<0.001 
<0.001 
 
TABLE 0:5 – APPROPRIATE ATP 
Rhythm 
group 
Episodes 
with 
appropriate 
ATP   
Appropriate 
ATP   
 
Rate 
of  appropriate 
ATP * 100 
patient/years 
(95%CI) 
Incidence rate ratio  
(95%CI) 
p-value 
SR 2255 2883 86.9 (83.8 - 90.2)   
AF+DRUG 330 412 97.6 (88.6 -  107) 1.12 (0.87 - 1.45) vs. SR 0.38 
AF+AVJA 132 136 45.1 (38.1 - 53.3) 
0.72 (0.58 - 0.89) vs. SR 
0.46 (0.31 - 0.69) vs. AF+DRUG 
0.003 
<0.001 
 
TABLE 0:6 – APPROPRIATE SHOCKS 
Group 
Number of episodes 
with appropriate 
shocks 
Rate of  episodes with 
appropriate shocks *100 
patient years 
(95%CI) 
Incidence rate ratio (95%CI) p-value 
SR 498 15.0 (13.8 - 16.4)   
AF+DRUG 97 23.0 (18.8 - 28.0) 1.53 (1.19 - 1.96) vs. SR <0.001 
AF+AVJA 16 5.3 ( 3.2 -  8.7) 
0.59 (0.45 - 0.78) vs. SR 
0.23 (0.13 - 0.40) vs. AF+DRUG 
<0.001 
<0.001 
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Inappropriate  detections, ATP and shocks 
TABLE 0:7 – INAPPROPRIATE DETECTIONS  
Rhythm 
group 
Inappropriate  
Detections  
Rate of inappropriate  
detections * 100 patient/years 
(95%CI) 
Incidence rate ratio  
(95%CI) 
p-value 
SR 1212 36.5 (34.5 - 38.7)   
AF+DRUG 179 42.4 (36.6 - 49.1) 1.16 (0.90 - 1.49) vs. SR 0.240 
AF+AVJA 14 4.6 ( 2.7 -  7.8) 
0.36 (0.24 - 0.53) vs. SR 
0.11 (0.05 - 0.22) vs. AF+DRUG 
<0.001 
<0.001 
 
TABLE 0:8 – INAPPROPRIATE ATP  
Rhythm 
group 
Episodes with 
inappropriate  
ATP   
Inappropriate 
ATP   
Rate of  
inappropriate ATP * 
100 
patient/years 
(95%CI) 
Incidence rate ratio  
(95%CI) 
p-value 
SR 610 811 
24.5  
(22.8 - 26.2) 
  
AF+DRUG 91 109 
25.8  
(21.4 - 31.2) 
1.06 (0.79 - 1.41) vs. SR 0.71 
AF+AVJA 5 5 
1.7  
(0.7 -  4.0) 
0.26 (0.14 - 0.48) vs. SR 
0.06 (0.02 - 0.18) vs. AF+DRUG 
<0.001 
<0.001 
TABLE 0:9 – INAPPROPRIATE SHOCKS  
Group 
Number of episodes 
with inappropriate 
shocks 
Rate of episodes with 
inappropriate shocks * 100 
patient years (95%CI) 
Incidence rate ratio  
(95%CI) 
p-value 
SR 305 9.2 ( 8.2 - 10.3)   
AF+DRUG 50 11.8 ( 9.0 - 15.6) 1.29 (0.98 - 1.69) vs. SR 0.067 
AF+AVJA 4 1.3 ( 0.5 -  3.5) 
0.38 (0.25 - 0.58) vs. SR 
0.11 (0.05 - 0.24) vs. AF+DRUG 
<0.001 
<0.001 
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AF-related inappropriate detections, ATP and shocks  
TABLE 0:10 – AF-RELATED INAPPROPRIATE DETECTIONS 
Rhythm 
group 
AF-related 
inappropriate  
detections  
Rate  
of  AF-related inappropriate 
detections*100 patient/years 
(95%CI) 
Incidence rate ratio  
(95%CI) 
p-value 
SR 935 28.2 (26.4 - 30.1)   
AF+DRUG 157 37.2 (31.8 - 43.5) 1.32 (1.03 - 1.69) vs. SR 0.028 
AF+AVJA 12 4.0 (2.3 -  7.0) 
0.38 (0.25 - 0.56) vs. SR 
0.11 (0.05 - 0.23) vs. AF+DRUG 
<0.001 
<0.001 
 
TABLE 0:11 – AF-RELATED INAPPROPRIATE ATP 
Rhythm 
group 
Episodes with 
AF-related 
inappropriate  
ATP   
AF-related 
inappropriate 
ATP   
Rate of AF-related 
inappropriate ATP * 
100 patient/years 
(95%CI) 
 
Incidence rate ratio  
(95%CI) 
 
p-value 
SR 561 735 22.2 (20.6 - 23.8)   
AF+DRUG 89 107 25.3 (21.0 - 30.6) 1.14 (0.86 - 1.52) vs. SR 0.35 
AF+AVJA 3 3 1.0 ( 0.3 -  3.1) 
0.21 (0.10 - 0.45) vs. SR 
0.04 (0.01 - 0.14) vs. AF+DRUG 
<0.001 
<0.001 
 
TABLE 0:12 – AF-RELATED INAPPROPRIATE SHOCKS 
Rhythm 
group 
Episodes with 
AF-related 
inappropriate 
shocks 
AF-related 
inappropriate 
shocks  
 
 
Rate of AF-related 
inappropriate shocks 
*100 patient/years 
(95%CI) 
Incidence rate ratio  
(95%CI) 
p-value 
SR 261 418 12.6 (11.5 - 13.9)   
AF+DRUG 37 49 11.6 (8.8 - 15.4) 0.92 (0.67 - 1.27) vs. SR 0.61 
AF+AVJA 2 2 0.7 (0.2 -  2.7) 
0.23 (0.11 - 0.48) vs. SR 
0.06 (0.02 - 0.16) vs. AF+DRUG 
<0.001 
<0.001 
 
 
